Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation

Health Physics

Volumn 99, Issue 3, 2010, Pages 408-412

  Miller, Scott C ^b   Wang, Xuli ^b   Bowman, Beth M ^a  

^a UNIVERSITY OF UTAH   (United States)

^b NONE

Author keywords

14C; 241AM; actinides; chelation

Indexed keywords

ACETIC ACID DERIVATIVE; AMERICIUM; CARBON; CHELATING AGENT; DOCOSYL TRIETHYLENETETRAMINEPENTAACETIC ACID; DOCOSYL-TRIETHYLENETETRAMINEPENTAACETIC ACID; DRUG DERIVATIVE; PENTETIC ACID; PLUTONIUM; TRIENTINE;

AUTORADIOGRAPHY; BIOAVAILABILITY; CHEMISTRY; CONFERENCE PAPER; DRUG EFFECT; INTESTINE ABSORPTION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SYNTHESIS; WASTE MANAGEMENT; ANALOGS AND DERIVATIVES; DRUG EFFECTS; PROCEDURES; TOXICITY;

ACETIC ACIDS; ADMINISTRATION, ORAL; AMERICIUM; AUTORADIOGRAPHY; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CHELATING AGENTS; DECONTAMINATION; INTESTINAL ABSORPTION; PENTETIC ACID; PLUTONIUM; TRIETHYLENETETRAMINE; ACETATES; TRIENTINE;

EID: 77955639048     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/HP.0b013e3181bfb99b     Document Type: Conference Paper

References (22)

1. Anderegg G, Arnaud-Neu F, Delgado R, Felcman J, Popov K. Critical evaluation of stability constants of metal complexes of complexones for biomedical and environmental applications (IUPAC Technical Report). Pure Appl Chem 77:1445- 1495; 2005.
2. Bruenger FW, Kuswik-Rabiega G, Miller SC. Decorporation of aged actinide deposits by oral administration of lipophilic polyaminocarboxylic acids. J Med Chem 35:112-118; 1992.
3. Durbin PW. Actinides in animals and man. In: Morris LR, Edelstein NM, Luger J, eds. The chemistry of the actinides and lanthanide elements. Dordrecht, The Netherlands: Springer; 2006: 3339-3440.
4. Durbin PW. Lauriston S. Taylor Lecture: The quest for therapeutic actinide chelators. Health Phys 95:465-492; 2008.
5. Harmuth-Hoene AE, Catsch A, Nigrovic V, Bohne F. Excretion of 65Zn-DTPA in the rat. Int J Radiat Biol Relat Stud Phys Chem Med 10:479-483; 1966.
6. James AC, Sasser LB, Stuit DB, Glover SE, Carbaugh EH. USTUR whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu. Radiat Protect Dosim 127:449- 455; 2007.
7. Leggett RW, Eckerman KF, Khokhryakov VF, Suslova KG, Krahenbuhl MP, Miller SC. Mayak worker study: an improved biokinetic model for reconstructing doses from internally deposited plutonium. Radiat Res 164:111-122; 2005.
8. Liu G, Men P, Kenner GH, Miller SC. Age-associated iron accumulation in bone: implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation. Biometals 19:245-251; 2006.
9. Liu G, Men P, Kenner G, Miller SC. Therapeutic effects of an oral chelator targeting skeletal tissue damage in experimental postmenopausal osteoporosis in rats. Hemoglobin 32:1- 10; 2008.
10. Miller SC, Bruenger FW, Kuswik-Rabiega GK, Lloyd RD. The decorporation of plutonium by the oral administration of a partially lipophilic polyaminocarboxylic acid. Health Phys 63:195-197; 1992.
11. Miller SC, Bruenger FW, Kuswik-Rabiega G, Liu G, Lloyd RD. Duration and dose-related effects of an orally administered, partially lipophilic polyaminocarboxylic acid on the decorporation of plutonium and americium. J Pharm Exp Therap 267:548 -554; 1993.
12. Miller SC, Liu G, Bruenger FW, Lloyd RD. Efficacy of orally administered amphipathic polyaminocarboxylic acid chelators for removal of plutonium and americium: comparison with injected Zn-DTPA. Radiat Protect Dosim 118:412- 420; 2006.
13. Mycyk MB, Leikin JB. Combined exchange transfusion and chelation therapy for neonatal lead poisoning. Ann Pharmacother 38:821- 824; 2004.
14. Polig E, Bruenger FW, Lloyd RD, Miller SC. Biokinetic and dosimetry model of plutonium in the dog. Health Phys 78:182-190; 2000.
15. Sonoda M, Yoshida I, Murase I. Synthesis and determination of metal chelate stabilities of n-alkyltriethylenetetraaminepentaacetic acid. J Coord Chem 54:153-165; 2001.
16. Stradling GN, Gray SA, Ellender M, Pearce M, Wilson I, Moody JC, Hodgson A. Removal of inhaled plutonium and americium from the rat by administration of ZnDTPA in drinking water. Hum Exp Toxicol 12:233-239; 1993.
17. Suslova KG, Khokhryakov VF, Tokarskaya ZB, Nifatov AP, Krahenbuhl MP, Miller SC. Extrapulmonary organ distribution of plutonium in healthy workers exposed by chronic inhalation at the Mayak Production Association. Health Phys 82:432- 444; 2002.
18. Suslova KG, Khokhryakov VF, Tokarskaya ZB, Nifatov AP, Sokolova AB, Miller SC, Krahenbuhl MP. Modifying effects of health status, physiological, and dosimetric factors on extrapulmonary organ distribution and excretion of inhaled plutonium in workers at the Mayak Production Association. Health Phys 90:299 -311; 2006.
19. Taylor DM, Hodgson SA, Stradling N. Treatment of human contamination with plutonium and americium: Would orally administered Ca- or Zn-DTPA be effective? Radiat Protect Dosim 127:469-471; 2007.
20. U.S. Food and Drug Administration. FDA approved drugs to treat internal contamination from radioactive elements. Washington, DC: U.S. FDA; FDA Press Release P04-78; 2004.
21. White DL, Durbin PW, Jeung N, Raymond KN. Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands. J Med Chem 31:11-18; 1988.
22. Wood R, Sharp C, Gourmelon P, Le Guen B, Stradling GN, Taylor DM, Henge-Napoli MH. Decorporation treatment- medical overview. Radiat Protect Dosim 87:51-57; 2000.